Cardiovascular Diseases
At Centrul Medical Unirea S.R.L. researchers are investigating a range of heart‑related conditions, with the goal of testing innovative therapies that reduce cardiovascular events and improve patient quality of life.
- Acute myocardial infarction (AMI)
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Established cardiovascular disease
- High cardiovascular risk
- Elevated Lp(a)
- Hypertension
- Uncontrolled and resistant hypertension
- Heart failure (HF)
- Heart failure with preserved ejection fraction (HFpEF)
Ongoing studies evaluate combinations such as a novel lipid‑lowering agent with standard heart‑failure medication to see if they can further lower the risk of cardiovascular death and hospitalisation.
Female Urogenital Diseases and Pregnancy Complications
Clinical work at the site includes trials focused on conditions that affect women’s reproductive health, aiming to discover treatments that alleviate pain and improve daily functioning.
- Endometriosis
- Endometriosis‑related pain
- Urinary incontinence
- Stress‑related urinary leakage
One study assesses a new oral compound for reducing endometriosis‑associated lesions, while another evaluates a novel agent designed to strengthen pelvic floor control in women with incontinence.
Immune System Diseases
Researchers are exploring immune‑mediated disorders, testing biologics and allergen‑specific therapies to lessen inflammation and improve symptom control.
- Atopic dermatitis
- Birch pollen‑induced allergic rhinoconjunctivitis
- Seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen
- Chronic rhinosinusitis with nasal polyps (CRSwNP)
Trials include a pediatric study of a grass‑pollen vaccine and an investigation of an IL‑33 inhibitor for reducing nasal polyp size in adults.
Neoplasms
The oncology program at the hospital evaluates targeted and immunotherapy approaches for difficult‑to‑treat cancers, seeking to improve survival and disease‑free intervals.
- High‑risk non‑muscle‑invasive bladder cancer
- KRAS/NRAS and BRAF wild‑type recurrent unresectable or metastatic colorectal cancer
One investigation compares an intravesical chemotherapy regimen with physician‑chosen alternatives after BCG failure, while another tests a combination of a novel antibody with standard chemotherapy in colorectal cancer patients.
Nutritional and Metabolic Diseases
Metabolic research at the site targets lipid disorders, aiming to lower triglyceride levels and modify lipoprotein profiles to reduce cardiovascular risk.
- Severe hypertriglyceridemia (SHTG)
- Elevated Lp(a)
A phase‑3 trial evaluates an RNA‑based therapy for its ability to decrease fasting triglycerides, while another study examines a small‑molecule inhibitor for lowering Lp(a) concentrations.
Otorhinolaryngologic Diseases
Studies in ear, nose and throat medicine focus on chronic sinus disease and allergic conditions, testing both pharmacologic and immunologic interventions.
- Chronic rhinosinusitis with nasal polyps (CRSwNP)
- Birch pollen‑induced allergic rhinoconjunctivitis
- Seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen
Researchers are measuring changes in nasal congestion, polyp size, and quality‑of‑life scores to determine whether new biologics or allergen extracts provide superior relief compared with standard intranasal steroids.
Respiratory Tract Diseases
The department also addresses broader respiratory ailments, exploring how allergic triggers and inflammation affect airway health.
- Allergic rhinitis
- Asthma‑like symptoms associated with pollen exposure
Ongoing work includes evaluating a sublingual immunotherapy tablet for long‑term control of pollen‑induced respiratory symptoms in children and adolescents.
Skin and Connective Tissue Diseases
Dermatology‑focused trials aim to improve outcomes for patients with inflammatory skin conditions by testing novel biologics alongside standard topical treatments.
- Atopic dermatitis
One study measures the impact of an anti‑IL‑13 antibody on itch severity, skin barrier function, and overall quality of life in young children with moderate‑to‑severe disease.
